Patients with stage IV hemangioimmunoblastic T-cell lymphoma have severe disease that requires immediate treatment.
Angioimmunoblastic T-cell lymphoma is a type of non-Hodgkin’s lymphoma that is highly aggressive (i.e., highly malignant), progresses rapidly, and has a less-than-ideal overall treatment outcome, making it difficult to cure.
Patients with Ann Arbor stage IV hemangioimmunoblastic T-cell lymphoma have lesions involving one or more extranodal organs, or involving the liver or bone marrow. These patients have severe disease and worse prognosis. Therefore, patients with stage IV hemangioimmunoblastic T-cell lymphoma are in serious condition.
It is recommended that the patient should immediately go to the Department of Hematology, and the specialist should formulate an individualized treatment plan according to the specific condition, and actively provide targeted therapy (cedarbenazine), combined chemotherapy (cyclophosphamide, vincristine) or bone marrow transplantation to prolong the patient’s survival and improve the quality of life as much as possible.